Good morning :)
$
₹
Insmed Inc

Insmed Inc

INSM

NASDAQ
Asset Logo

Insmed Inc

INSM

NASDAQ
$106.73% (-3.3)
$
₹
$106.73% (-3.3)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $22.9B the stock is ranked 559

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

33.02
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.81
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.09
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-39.85%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 24 analysts reports

Buy
23 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+76.53%

Earnings Growth

+72.85%

Rev. Growth

+206.64%

See Detailed Forecast

Company Profile

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 76.53% growth, versus a trailing 3-year CAGR of 66.48%.

2026
Current$110Baseline
Analyst Target - 1 year
Target$194.18+76.53%

All values in $

202220232024202520262027$66.89$115.79$164.69Target+76.53%
2026
Current$110Baseline
Analyst Target - 1 year
Target$194.18+76.53%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 206.64% growth, versus a trailing 3-year CAGR of 35.20%.

2025
Current$606.42Baseline
Forecast for Dec 2026
High$1,889.18+211.53%
Average$1,859.52+206.64%
Low$1,824.5+200.86%

All values in $ Million

202120222023202420252026188.46245.35305.20363.70606.42Low+200.86%Average+206.64%High+211.53%
2025
Current$606.42Baseline
Forecast for Dec 2026
High$1,889.18+211.53%
Average$1,859.52+206.64%
Low$1,824.5+200.86%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-6.41Baseline
Forecast for Dec 2026
High$-1.31+79.56%
Average$-1.74+72.85%
Low$-2.17+66.15%

All values in $

202120222023202420252026-3.71-3.9-5.34-5.59-6.41Low+66.15%Average+72.85%High+79.56%
2025
Current$-6.41Baseline
Forecast for Dec 2026
High$-1.31+79.56%
Average$-1.74+72.85%
Low$-2.17+66.15%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

263.8
-328.4
305.9
-163.5
425.4
-13.2
524.4
-100.3
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue90.3493.42104.4492.82107.41142.34263.84305.96425.48524.42
Net Income-300.60-220.52-235.54-256.58-321.68-370.02-328.48-163.56-13.24-100.31
Net Profit Margin-332.75%-236.04%-225.52%-276.42%-299.47%-259.95%-124.50%-53.45%-3.11%-19.12%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Insmed Inc -33.021.09
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare INSM with any stock or ETF
Compare INSM with any stock or ETF
Comparing from
INSM
ABBV
AMGN
Loading...

Frequently asked questions

  1. Insmed Inc (INSM) share price today is $106.70 as of November 6, 2026 at 12:10 AM IST. The stock touched a day high of $109.78 and a day low of $106.23.

  2. Insmed Inc stock trades on NASDAQ under the ticker symbol INSM.

  3. Insmed Inc's market capitalization is $22.91B as of November 6, 2026 at 12:10 AM IST.

  4. Insmed Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Insmed Inc's price-to-book (P/B) ratio is 33.02 as of November 5, 2026.

  6. Yes, You can buy Insmed Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Insmed Inc shares in three steps: 1. Search Insmed Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Insmed Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Insmed Inc (INSM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0937 shares at the current price of $106.70.

Loading...